Current and future therapies for idiopathic pulmonary fibrosis

Clinical Pulmonary Medicine

Volumn 18, Issue 6, 2011, Pages 257-264

  Maher, Toby M ^a,b,c  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

^b NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Interstitial lung disease; nonspecific interstitial pneumonia; pirfenidone; treatment; usual interstitial pneumonia

Indexed keywords

ACETYLCYSTEINE; ANTIFIBROTIC AGENT; AZATHIOPRINE; BOSENTAN; CORTICOSTEROID; COTRIMOXAZOLE; ENDOTHELIN RECEPTOR ANTAGONIST; ETANERCEPT; GAMMA INTERFERON; GAMMA1B INTERFERON; IMATINIB; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 13; LOW MOLECULAR WEIGHT HEPARIN; PHOSPHODIESTERASE INHIBITOR; PIRFENIDONE; PLACEBO; PREDNISOLONE; PROSTACYCLIN DERIVATIVE; PROSTAGLANDIN E2; SILDENAFIL; THALIDOMIDE; TRANSFORMING GROWTH FACTOR BETA; WARFARIN;

ACUTE RESPIRATORY FAILURE; ANTIBIOTIC THERAPY; ANTICOAGULANT THERAPY; ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL PROLIFERATION; CORTICOSTEROID THERAPY; COUGHING; DISEASE COURSE; DISEASE EXACERBATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; DYSPNEA; FIBROSING ALVEOLITIS; HUMAN; HYPERCAPNIA; INTERSTITIAL PNEUMONIA; LUNG FIBROBLAST; LUNG TRANSPLANTATION; NONHUMAN; PATIENT COMPLIANCE; PULMONARY HYPERTENSION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); STAPHYLOCOCCUS AUREUS; THROMBOEMBOLISM; TISSUE REPAIR; UNSPECIFIED SIDE EFFECT; WEGENER GRANULOMATOSIS; WOUND HEALING;

EID: 80455150118     PISSN: 10680640     EISSN: 15365956     Source Type: Journal    
DOI: 10.1097/CPM.0b013e3182350bb4     Document Type: Article

References (47)

1. Raghu G, Weycker D, Edelsberg J, et al. Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2006;174:810-816.
2. Maher TM, Wells AU, Laurent GJ. Idiopathic pulmonary fibrosis: Multiple causes and multiple mechanisms? Eur Respir J. 2007;30:835-839.
3. American Thoracic Society. Idiopathic pulmonary fibrosis: Diagnosis and treatment. International consensus statement American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med. 2000;161:646-664.
4. Selman M, King TE, Pardo A. Idiopathic pulmonary fibrosis: Prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med. 2001;134:136-151.
5. Singer AJ, Clark RA. Cutaneous wound healing. N Engl J Med. 1999;341:738-746.
6. Kuhn C III, Boldt J, King TE Jr., et al. An immunohistochemical study of architectural remodeling and connective tissue synthesis in pulmonary fibrosis. Am Rev Respir Dis. 1989;140: 1693-1703.
7. Katzenstein AL, Myers JL. Idiopathic pulmonary fibrosis: Clinical relevance of pathologic classification. Am J Respir Crit Care Med. 1998;157:1301-1315.
8. Barbas-Filho JV, Ferreira MA, Sesso A, et al. Evidence of type II pneumocyte apoptosis in the pathogenesis of idiopathic pulmonary fibrosis (IFP)/usual interstitial pneumonia (UIP). J Clin Pathol. 2001;54:132-138.
9. Kuwano K, Kunitake R, Maeyama T, et al. Attenuation of bleomycin-induced pneumopathy in mice by a caspase inhibitor. Am J Physiol Lung Cell Mol Physiol. 2001;280:L316-L325.
10. Antoniou KM, Hansell DM, Rubens MB, et al. Idiopathic pulmonary fibrosis: Outcome in relation to smoking status. Am J Respir Crit Care Med. 2008;177:190-194.
11. Hubbard R, Lewis S, Richards K, et al. Occupational exposure to metal or wood dust and aetiology of cryptogenic fibrosing alveolitis. Lancet. 1996;347:284-289.
12. Egan JJ, Stewart JP, Hasleton PS, et al. Epstein-Barr virus replication within pulmonary epithelial cells in cryptogenic fibrosing alveolitis. Thorax. 1995;50:1234-1239.
13. Raghu G, Freudenberger TD, Yang S, et al. High prevalence of abnormal acid gastro-oesophageal reflux in idiopathic pulmonary fibrosis. Eur Respir J. 2006;27:136-142.
14. Zappala CJ, Latsi PI, Nicholson AG, et al. Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis. Eur Respir J. 2010;35:830-836.
15. Raghu G, Brown KK, Bradford WZ, et al. A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2004;350:125-133.
16. Demedts M, Behr J, Buhl R, et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med. 2005;353: 2229-2242.
17. Behr J, Demedts M, Buhl R, et al. Lung function in idiopathic pulmonary fibrosis-extended analyses of the IFIGENIA trial. Respir Res. 2009;10:101.
18. Maher TM. Pirfenidone in idiopathic pulmonary fibrosis. Drugs Today (Barc). 2010;46:473-482.
19. Raghu G, Johnson WC, Lockhart D, et al. Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: Results of a prospective, open-label Phase II study. Am J Respir Crit Care Med. 1999;159:1061-1069.
20. Azuma A, Nukiwa T, Tsuboi E, et al. Double-blind, placebocontrolled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2005;171: 1040-1047.
21. Taniguchi H, Ebina M, Kondoh Y, et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J. 2010;35:821-829.
22. Swigris J, Fairclough D. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J. 2010;36:695-696. Author reply 6-8.
23. Noble P, Albera C, Bradford W, et al. The CAPACITY (CAP) trials: Randomized double-blind, placebo-controlled, phase III trials of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF). Am J Respir Crit Care Med. 2009;179:A1129.
24. Spagnolo P, Del Giovane C, Luppi F, et al. Non-steroid agents for idiopathic pulmonary fibrosis. Cochrane Database Syst Rev. 2010;CD003134.
25. Keating D, Levvey B, Kotsimbos T, et al. Lung transplantation in pulmonary fibrosis: Challenging early outcomes counterbalanced by surprisingly good outcomes beyond 15 years. Transplant Proc. 2009;41:289-291.
26. Orens JB, Estenne M, Arcasoy S, et al. International guidelines for the selection of lung transplant candidates: 2006 update-a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2006;25:745-755.
27. Richeldi L, Davies HR, Ferrara G, et al. Corticosteroids for idiopathic pulmonary fibrosis. Cochrane Database Syst Rev. 2003; CD002880.
28. Raghu G, Depaso WJ, Cain K, et al. Azathioprine combined with prednisone in the treatment of idiopathic pulmonary fibrosis: A prospective double-blind, randomized, placebo-controlled clinical trial. Am Rev Respir Dis. 1991;144:291-296.
29. Chambers RC. Procoagulant signalling mechanisms in lung inflammation and fibrosis: Novel opportunities for pharmacological intervention? Br J Pharmacol. 2008;153:S367-S378.
30. Kubo H, Nakayama K, Yanai M, et al. Anticoagulant therapy for idiopathic pulmonary fibrosis. Chest. 2005;128:1475-1482.
31. Varney VA, Parnell HM, Salisbury DT, et al. A double blind radomized placebo controlled pilot study of oral co-trimoxazole in advanced fibrotic lung disease. Pulm Pharmacol Ther. 2008; 21:178-187.
32. King TE Jr., Albera C, Bradford WZ, et al. Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): A multicenter, radomized, placebocontrolled trial. Lancet. 2009;374:222-228.
33. King TE Jr., Behr J, Brown KK, et al. BUILD-1: A randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2008;177:75-81.
34. King J, Talmadge E Jr., Brown KK, et al. Prospective, randomized, double-blind, placebo-controlled study of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2010;181:A6838.
35. Raghu G, Brown KK, Costabel U, et al. Treatment of idiopathic pulmonary fibrosis with etanercept: An exploratory, placebo-controlled trial. Am J Respir Crit Care Med. 2008;178: 948-955.
36. Daniels CE, Lasky JA, Limper AH, et al. Imatinib treatment for idiopathic pulmonary fibrosis: Randomized placebo-controlled trial results. Am J Respir Crit Care Med. 2010;181:604-610.
37. Collard HR, Moore BB, Flaherty KR, et al. Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2007;176:636-643.
38. Nathan SD. Pulmonary hypertension in interstitial lung disease. Int J Clin Pract. 2008;160:21-28.
39. Corte TJ, Wort SJ, Wells AU. Pulmonary hypertension in idiopathic pulmonary fibrosis: A review. Sarcoidosis Vasc Diffuse Lung Dis. 2009;26:7-19.
40. Collard HR, Anstrom KJ, Schwarz MI, et al. Sildenafil improves walk distance in idiopathic pulmonary fibrosis. Chest. 2007;131: 897-899.
41. Zisman DA, Schwarz M, Anstrom KJ, et al. A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. N Engl J Med. 2010;363:620-628.
42. Nishiyama O, Kondoh Y, Kimura T, et al. Effects of pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis. Respirology. 2008;13:394-399.
43. Swigris JJ, Brown KK, Make BJ, et al. Pulmonary rehabilitation in idiopathic pulmonary fibrosis: A call for continued investigation. Respir Med. 2008;102:1675-1680.
44. Horton MR, Danoff SK, Lechtzin N. Thalidomide inhibits the intractable cough of idiopathic pulmonary fibrosis. Thorax. 2008;63:749.
45. Maher TM, Wells AU. Lost in translation; from animal models of pulmonary fibrosis to human disease. Respirology. 2009;14:915-916.
46. Mizuno S, Matsumoto K, Li MY, et al. HGF reduces advancing lung fibrosis in mice: A potential role for MMP-dependent myofibroblast apoptosis. FASEB J. 2005;19:580-582.
47. Gomperts BN, Strieter RM. Fibrocytes in lung disease. J Leukoc Biol. 2007;82:449-456.